vitality

PT-141 (Bremelanotide)

Melanocortin Receptor Agonist

Best For

Sexual health support, desire-based dysfunction, non-vascular approach to arousal

FDA

Approved in 2019 as Vyleesi for HSDD

MC4R

Primary receptor target in the hypothalamus

~45min

Typical onset of action after administration

How It Works

PT-141 is a cyclic heptapeptide that activates melanocortin receptors MC3R and MC4R in the central nervous system, specifically within the hypothalamus and limbic system. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 initiates arousal through a top-down neural pathway — modulating dopaminergic signaling in brain regions associated with sexual motivation and desire. It is the active metabolite of Melanotan II, engineered to retain melanocortin activity while eliminating melanogenic effects. The compound received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Key Research Areas

Central Mechanism

Acts on brain melanocortin receptors — not peripheral vasculature

Desire Pathway

Enhances sexual motivation and arousal through dopaminergic modulation

Gender Applicability

Research supports efficacy in both male and female sexual dysfunction

PDE5 Alternative

Effective option for individuals who do not respond to vascular-targeted agents

Research Highlights

Only FDA-approved peptide that addresses sexual desire through central nervous system pathways
Effective in populations that do not respond to PDE5 inhibitors

Featured Research

PT-141: What the Research Shows About Melanocortin-Based Sexual Health

Read Sol's deep dive →

Formulation Notes

Common concentrations referenced in published clinical studies:

[P41]10mg